Monitor the KOL webinar on August 19 for TTI-109's UC potential and the Q4 2026 TTI-101 HCC data readout. Cash runway extends through Q3 2027 but TTI-109 advancement requires external financing — watch for equity offerings or partnership announcements.
Price Chart
Executive Summary
Tvardi Therapeutics reported Q2 2026 EPS of -$0.73, a 15.6% miss vs consensus of -$0.63, with no revenue. Pipeline progress included positive healthy volunteer data for next-generation STAT3 inhibitor TTI-109 and selection of ulcerative colitis as the initial indication, but cash burn reduced reserves to $15.8M, requiring additional funding for TTI-109's UC trial.
Key Financial Metrics
Key Facts
- Q2 2026 EPS -$0.73 vs consensus -$0.63 (15.6% miss)
- No revenue (pre-revenue clinical-stage biopharma)
- Net loss $6.5M vs net income $4.2M in Q2 2025 (prior year included $12.7M non-cash gain)
- Cash, cash equivalents and short-term investments $15.8M as of June 30, 2026, down from $30.8M at Dec 31, 2025
- Positive healthy volunteer results for TTI-109: improved tolerability and pharmacodynamic evidence of STAT3 target engagement
- Selected ulcerative colitis as initial indication for TTI-109; KOL webinar scheduled Aug 19, 2026
- TTI-101 Phase 1b/2 HCC topline data expected in Q4 2026
- TTI-109 UC trial initiation in 2027 subject to IND clearance and additional funding
Financial Impact
EPS miss of $0.10 per share (15.6% below consensus); cash burn of ~$15M in six months; no revenue impact
Risk Factors
- Need for additional capital to fund TTI-109 UC trial and ongoing operations
- Clinical trial risks for TTI-101 and TTI-109
- Cash burn rate may accelerate with expanded pipeline activities
- No approved products or revenue; reliance on pipeline success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345230 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | Institutional Cluster | $1.86 $1.61 | ▲ +13.44% | ▲ +12.91% | $0.8700 (+53.23%) |
Aug 14, 2026 10w ago | 8-K | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8700 (−54.21%) |
Aug 14, 2026 10w ago | Press Release | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8700 (−54.21%) |
Jul 30, 2026 12w ago | 8-K | $2.10 $1.80 | ▼ −14.29% | ▼ −18.25% | $0.8700 (−58.57%) |
Jul 7, 2026 16w ago | 8-K | $3.10 $2.02 | ▼ −34.84% | ▼ −36.17% | $0.8700 (−71.94%) |
May 14, 2026 23w ago | EFFECT | $3.96 $2.64 | ▲ +33.33% | ▲ +32.48% | $0.8700 (+78.03%) |
May 13, 2026 23w ago | EFFECT | $3.95 $2.71 | ▲ +31.39% | ▲ +30.78% | $0.8700 (+77.97%) |
May 8, 2026 24w ago | Press Release | $4.18 $2.89 | ▼ −30.86% | ▼ −30.88% | $0.8700 (−79.19%) |
Apr 23, 2026 26w ago | DEFA14A | $3.10 $3.59 | ▲ +15.81% | ▲ +11.78% | $0.8700 (−71.94%) |
Mar 31, 2026 29w ago | 8-K | $3.00 $3.06 | ▲ +2.00% | ▼ −7.72% | $0.8700 (−71.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers